Cannabinoid Encyclopedia

Focused research review

Cannabinoids and cardiovascular risk: what the research says

Which cannabinoid evidence requires heightened review for cardiovascular risk?

Updated July 2026 7 research sources Mostly early-stage research

The short answer

What is the bottom line?

Research has examined Cannabinoids and cardiovascular risk. This page brings together 5 research reviews and 1 lab, animal, or mechanism source. Most of the current evidence is preclinical or focused on biological mechanisms. The studies do not all test the same product, dose, group of people, or outcome, so they cannot be reduced to one answer for every person or product. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about Cannabinoids and cardiovascular risk.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Research on Cannabinoids and cardiovascular risk covers Safety, risk, adverse-event, or formulation-specific concerns; those areas should not be combined into one claim. 1

  2. 2

    Most of the current evidence is preclinical or focused on biological mechanisms. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What researchers studied about Cannabinoids and cardiovascular risk

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Too limited for a firm answer

Safety, risk, adverse-event, or formulation-specific concerns

This part of the literature focuses on Safety, risk, adverse-event, or formulation-specific concerns. Studies may use different compounds, formulations, doses, routes, groups of people, and outcomes, so the details of each source matter. 2

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

Not prominent

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

5 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

1 source

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

Another 1 of 7 research source could not be placed cleanly into those three groups from the recorded study details.

What these studies actually looked at

The research on Cannabinoids and cardiovascular risk is not one kind of study. This source set includes 4 narrative or expert reviews, 1 animal study, and 1 systematic review or meta-analysis. 3

The recorded populations or models include people or patients (4 sources) and animal models (1 source). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is safety, risk, adverse-event, or formulation-specific concerns (7 sources). Closely related outcome names can still describe different measurements. 5

The Cannabinoids and cardiovascular risk source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

systematic review or meta-analysis

Cannabis use and acute coronary syndrome.

On this page, this source examines Cannabinoids and safety, risk, adverse-event, or formulation-specific concerns. 1

Study type
systematic review or meta-analysis
Population or model
people or patients
Outcome focus
safety, risk, adverse-event, or formulation-specific concerns
Evidence stage
evidence still limited

narrative or expert review

Role of cannabis in cardiovascular disorders.

On this page, this source examines Endocannabinoids and safety, risk, adverse-event, or formulation-specific concerns. 2

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
safety, risk, adverse-event, or formulation-specific concerns
Evidence stage
evidence still limited

animal study

Increased vulnerability to atrial and ventricular arrhythmias caused by different types of inhaled tobacco or marijuana products.

On this page, this source examines Cannabinoids and safety, risk, adverse-event, or formulation-specific concerns. 3

Study type
animal study
Population or model
animal models
Outcome focus
safety, risk, adverse-event, or formulation-specific concerns
Evidence stage
preclinical research

narrative or expert review

Cardiovascular consequences of marijuana use.

On this page, this source examines THC and safety, risk, adverse-event, or formulation-specific concerns. 4

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
safety, risk, adverse-event, or formulation-specific concerns
Evidence stage
evidence still limited

narrative or expert review

Endocannabinoids, blood pressure and the human heart.

On this page, this source examines Endocannabinoids and safety, risk, adverse-event, or formulation-specific concerns. 5

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
safety, risk, adverse-event, or formulation-specific concerns
Evidence stage
evidence still limited

Safety and limits

What should readers keep in mind?

Research on Cannabinoids and cardiovascular risk should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

Which cannabinoid evidence requires heightened review for cardiovascular risk?

Relevant research is collected here. Most of the current evidence is preclinical or focused on biological mechanisms. 7

Why is there not always a yes-or-no answer?

The sources may test different products, doses, people, and outcomes, so a single conclusion can hide important differences. 1

Where can I read the original studies?

Use the numbered citations and the source list at the bottom of the page to open PubMed or DOI records. 2

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Cannabis use and acute coronary syndrome. systematic review or meta-analysis; evidence still limited PubMed 30964363 DOI 10.1080/15563650.2019.1601735
  2. 2
    Role of cannabis in cardiovascular disorders. narrative or expert review; evidence still limited PubMed 28840009 DOI 10.21037/jtd.2017.06.104
  3. 3
    Increased vulnerability to atrial and ventricular arrhythmias caused by different types of inhaled tobacco or marijuana products. animal study; preclinical research PubMed 36603937 DOI 10.1016/j.hrthm.2022.09.021
  4. 4
    Cardiovascular consequences of marijuana use. narrative or expert review; evidence still limited PubMed 12412838 DOI 10.1002/j.1552-4604.2002.tb06005.x
  5. 5
    Endocannabinoids, blood pressure and the human heart. narrative or expert review; evidence still limited PubMed 18426501 DOI 10.1111/j.1365-2826.2008.01677.x
  6. 6
    Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? narrative or expert review; evidence still limited PubMed 17005273 DOI 10.1016/j.ijcard.2006.08.001
  7. 7
    Acute Effects of Cannabis Inhalation on Arterial Stiffness, Vascular Endothelial Function, and Cardiac Function. evidence still limited PubMed 39575727 DOI 10.1161/jaha.124.037731
See all 7 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Role of cannabis in cardiovascular disorders. narrative or expert review; evidence still limited / 1 linked research note PubMed 28840009
  2. Increased vulnerability to atrial and ventricular arrhythmias caused by different types of inhaled tobacco or marijuana products. animal study; preclinical research / 1 linked research note PubMed 36603937
  3. Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? narrative or expert review; evidence still limited / 1 linked research note PubMed 17005273
  4. Cardiovascular consequences of marijuana use. narrative or expert review; evidence still limited / 1 linked research note PubMed 12412838
  5. Acute Effects of Cannabis Inhalation on Arterial Stiffness, Vascular Endothelial Function, and Cardiac Function. evidence still limited / 1 linked research note PubMed 39575727
  6. Cannabis use and acute coronary syndrome. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 30964363
  7. Endocannabinoids, blood pressure and the human heart. narrative or expert review; evidence still limited / 1 linked research note PubMed 18426501